Skip to main
LFMD

LifeMD (LFMD) Stock Forecast & Price Target

LifeMD (LFMD) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LifeMD is expected to achieve a 12-month price target of $10 per share due to its strong sales and expanding services in core areas such as Women's Health and weight management, in addition to strategic partnerships with major pharmaceutical companies. However, competition and potential risks, as well as a negative adjusted EBITDA in the first quarter of 2026, may affect reaching this target. Overall, the company's growth and collaborations show promise, but investors should carefully consider potential risks before making investment decisions.

Bears say

LifeMD is heavily investing in unapproved peptides, which may offer high margins, but carry potential risks due to lack of FDA approval. While the company expects strong revenue and EBITDA growth in the future, there are significant risks that could hinder their success, including cybersecurity threats, product recalls, and overall market demand. With a highly regulated healthcare market and a history of losses, there are uncertainties surrounding the company's ability to maintain profitability and effectively execute their growth strategies.

LifeMD (LFMD) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LifeMD (LFMD) Forecast

Analysts have given LifeMD (LFMD) a Strong Buy based on their latest research and market trends.

According to 7 analysts, LifeMD (LFMD) has a Strong Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LifeMD (LFMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.